AstraZeneca in deal with Kangtai Bio to supply Covid-19 vaccine in China


BEIJING (Reuters) - AstraZeneca PLC has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.

To meet market demand in China, Shenzhen Kangtai is obliged to make sure it has an annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, and a capacity of at least.

This article is no longer available in our repository.

There could be multiple reasons for this.